Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fluvoxamine for Early Treatment of Covid-19: a Fully-remote, Randomized Placebo Controlled Trial

NCT04668950 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04668950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04668950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fluvoxamine for Early Treatment of Covid-19: a Fully-remote, Randomized Placebo Controlled Trial
Lead sponsor
Washington University School of Medicine
Phase
Phase 3
Overall status
Completed
Start date
December 22, 2020
Completion date
September 28, 2021
Enrollment
670 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus, covid19